Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Income towards Parent Company: 2023-2024

Historic Income towards Parent Company for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to -$161.3 million.

  • Zenas BioPharma's Income towards Parent Company fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 50.07%. This contributed to the annual value of -$161.3 million for FY2024, which is 334.62% down from last year.
  • According to the latest figures from FY2024, Zenas BioPharma's Income towards Parent Company is -$161.3 million, which was down 334.62% from -$37.1 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Income towards Parent Company registered a high of -$37.1 million during FY2023, and its lowest value of -$161.3 million during FY2024.
  • Over the past 2 years, Zenas BioPharma's median Income towards Parent Company value was -$99.2 million (recorded in 2023), while the average stood at -$99.2 million.
  • Data for Zenas BioPharma's Income towards Parent Company shows a maximum YoY plummeted of 334.62% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Zenas BioPharma's Income towards Parent Company stood at -$37.1 million in 2023, then tumbled by 334.62% to -$161.3 million in 2024.